Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115937 | 0.93 | PTGDR2 (1.00) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL5107440 | 0.92 | PTGDR2 (1.00) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL30538012 | 0.91 | PTGDR2 (1.00) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL5122847 | 0.91 | PTGDR2 (1.00) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL5115017 | 0.91 | PTGDR2 (0.87) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL5114061 | 0.84 | PTGDR2 (1.00) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL5121041 | 0.84 | PTGDR2 (1.00) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL5106741 | 0.82 | PTGDR2 (1.00) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL5113243 | 0.81 | PTGDR2 (1.00) | PTGDR2CYP3A4CYP2C9 | |
| SCHEMBL5119602 | 0.81 | PTGDR2 (0.82) | PTGDR2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | claimed |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | ACTELION PHARMACEUTICALS,LTD. (CH) | 2008-05-08 | — | — | US | claimed |
| US-8273740-B2 | antiallergen; not direct way to change nature of immunological response to allergen; G-protein-coupled \"chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)\" antagonist for prostaglandin PGD2, that mediates PGD2-dependent migration of blood Th2 cells; ; asthma, rhinitis, COPD | ACTELION PHARMACEUTICALS, LTD. (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | ACTELION PHARMACEUTICALS,LTD. (CH) | 2008-05-08 | — | — | US | disclosed |
| EP-1784182-A1 | 2-SULFANYL-BENZIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021418-A1 | 2-SULFANYL-BENZOIMIDAZOL-1-YL-ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108638-A1 | 2-Sulfanyl-Benzoimidazol-1-Yl-Acetic Acid Derivatives as Crth2 Antagonists | HRH2, HRH1, HRH3 | PTGDR2 12/4885CYP3A4 4625/4885CYP2C9 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.